Akribion Genomics discovers novel groundbreaking CRISPR nucleases and develops them into a new class of genetics-based cancer therapies and advanced genome editing tools. Akribion Genomics’ flexible CRISPR-based gene editing technology platform features distinct technology families (G-Dases®) with broad application in industrial biotechnology (and agriculture) and offers a groundbreaking technological advantage for therapeutic and diagnostic solutions. Akribion Genomics is committed to using its technology with high ethical standards to improve products, processes, and medical treatments. Our mission is to enable new treatment approaches in oncology by employing novel CRISPR technology that allows targeted cell depletion using RNA biomarkers. On top, we aim to provide access to advanced CRISPR genome editing technology with freedom-to-operate. All this is summarized in our motto and brand “Gediting.” Akribion Genomics is a company in founding and soon-to-be spin-off of Brain Biotec.
Something looks off?Portfolio Jobs
Browse through our portfolio jobs and select a suitable opportunity.
0
COMPANIES
0
JOBS